Five Prime Therapeutics to Host Research & Development Day on May 5, 2015

SOUTH SAN FRANCISCO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company will hold its first Research & Development Day event for the institutional investment community in New York City on May 5, 2015. The formal program and webcast will begin at 8:30 am ET and will conclude at approximately 11:45 am ET.

Five Prime will give in-depth presentations covering the biology, clinical development programs and target indications for two antibody therapeutics, FPA008 and FPA144, as well as provide a closer look into the company's immuno-oncology discovery platform and recent activities.

Planned presenters include senior executives from Five Prime's scientific, clinical and management team as well as featured guest speakers:

  • Charles S. Fuchs, M.D., M.P.H.: Director of the Center for Gastrointestinal Cancer at Dana-Farber Cancer Institute, the Robert T. and Judith B. Hale Chair in Pancreatic Cancer and Professor of Medicine at Harvard Medical School. Dr. Fuchs also leads the Dana-Farber Harvard Cancer Center Gastrointestinal Malignancies Program and the DF/HCC SPORE Grant in Gastrointestinal Cancers.
  • Robert Maki, M.D.: Professor of Medicine, Pediatrics, and Orthopaedics at Mount Sinai Hospital, and the Steven Ravitch Chair in Pediatric Hematology-Oncology. Dr. Maki treats adults and children with pigmented villonodular synovitis (PVNS) and sarcomas.
  • Antoni Ribas, M.D., Ph.D.: Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA). Dr. Ribas is also the Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC).

The live webcast will be accessible at or directly at Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference. For additional information, please email

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit

CONTACT: Amy Kendall, Corporate Communications 415-365-5776

Source:Five Prime Therapeutics, Inc.